跳至主要内容
临床试验/IRCT20090117001556N121
IRCT20090117001556N121尚未招募3 期

Adalimumab as a adjuvant therapy in modrate to sever MDD in patients with CRP greater than or equal to 3mgr/lit : a double blind and randomized Trial

Tehran University of Medical Sciences0 个研究点目标入组 50 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
尚未招募
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 60 years(—)
性别
All

入选标准

  • Presence of Major Depressive Disorder based on DSM-5 criteria
  • Baseline Hamilton Depression Rating Scale (HAM-D) (17-item) score of at least 19
  • CRP equals or more than 3mg/lit

排除标准

  • Psychotic symptoms
  • Any other mental disorder
  • Hypothyroidism
  • Cardiovascular disease
  • Pregnant or nursing women
  • History of tuberculosis
  • Autoimmune disease
  • Viral hepatitis
  • Chronic or recurrent infections
  • Receiving ECT during the last two months
  • Significant suicidal ideation
  • Substance use

研究者

相似试验